The immunosuppressive drug methotrexate (MTX) can be linked to an elevated risk of three types of skin cancer, a new study by University of Gothenburg researchers shows.
The safety profile and the actual known adverse effects of COVID-19 vaccines in at-risk and healthy individuals
Researchers discussed the safety of COVID-19 vaccines in healthy people and patients with autoimmunity or cardiac issues.
Messenger RNAs (mRNAs) contain chemical marks that are critical for antiviral defense in cells, according to a new study from researchers at Weill Cornell Medicine.
Researchers examined the associations between coronavirus disease 2019 (COVID-19) and incident autoimmune diseases.
A research team, led by Professor Sung Ho Park in the Department of Biological Sciences at UNIST announced the results of a study on osteoblasts that damage joint bones in patients with rheumatoid arthritis.
Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.
The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), used in the treatment of autoimmune diseases. Remicade is widely used for rheumatoid arthritis (RA) therapy. Biosimilars are biopharmaceutical drugs that have similar properties to other licensed therapies. Sandoz announced the […]
Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), or Cimzia (certolizumab), are less cost-effective compared to DMARD combination in triple therapy with Azulfidine (sulfasalazine), Plaquenil (hydroxychloroquine), and Trexall (methotrexate) in the treatment of rheumatoid arthritis (RA). Importantly, this triple therapy also was found to be […]
Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA) who have not responded to or are intolerant to disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX). The wholesale price of the new treatment is about 30 percent less […]
Group-based quality improvement sessions, based on the recommended “treat to target” (TTT) approach, can help rheumatologists improve the quality of their care for rheumatoid arthritis (RA) patients, a recent study suggests. Results of the study, “Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Results of the TRACTION Randomized Controlled Trial,” were […]